日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Toll-like receptor 3: a double-edged sword

Toll样受体3:一把双刃剑

Hsieh, Marvin L; Nishizaki, Daisuke; Adashek, Jacob J; Kato, Shumei; Kurzrock, Razelle

Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations

基于分子谱分析确定个体化癌症治疗的证据调查(I-PREDICT)N-of-1精准肿瘤学研究:分子谱分析匹配个体化给药的个性化药物组合

Sicklick, Jason K; Nishizaki, Daisuke; Miyashita, Hirotaka; Okamura, Ryosuke; Hahn, Michael E; Nikanjam, Mina; Fanta, Paul T; Piccioni, David E; Patel, Hitendra; Eskander, Ramez N; McKay, Rana R; Ross, Jeffrey S; Lee, J Jack; Lippman, Scott M; Kato, Shumei; Kurzrock, Razelle

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

泛 RAF 抑制剂艾沙非尼靶向 BRAF II/III 类非小细胞肺癌,揭示 ARAF-KSR1 耐药性和联合治疗策略。

Manabe Tadashi, Bergo Hannah C, Li Qingtian, Wang Tim Sen, Severson Paul, Miller Nichol, Lee Catherine, Yay Donderici Elifnur, Zhang Nicole, Wu Wei, Chou Yu-Ting, Kerr Daniel L, Allegakoen Paul, Grandinetti Kathryn B, Soroceanu Liliana, Pelham Robert J, Martin Eric S, Murphy Eric A, Khanna Vishesh, Neal Joel W, Chen Christopher T, Kato Shumei, Williams Richard, Bivona Trever G

Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer

超灵敏ctDNA监测揭示晚期癌症免疫治疗反应的早期预测因子

Nishizaki, Daisuke; Law, Allison; Li, Bailiang; Abbott, Charles; Chen, Yi; Lee, Suzanna; Pyke, Rachel; Keough, Kathleen; Daniels, Gregory A; Yeung, Kay T; Boyle, Sean M; Chen, Richard O; Kato, Shumei

Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond

II类主要组织相容性复合体转录激活因子(CIITA):影响癌症及其他领域的关键MHC-II调节因子

Low, Soon Khai; Fujiwara, Yu; Nishizaki, Daisuke; Kato, Shumei; Kurzrock, Razelle

Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies

从接受精准靶向治疗的高级别脑瘤患者中汲取的经验教训

Dişel, Umut; Kato, Shumei; Shreenivas, Aditya; Danyeli, Ayca Ersen; Ahluwalia, Manmeet S; Kurzrock, Razelle

Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory System

诱导型T细胞共刺激分子(ICOS)和ICOS配体:应对癌症免疫调节系统的双重作用

Nikanjam, Mina; Kato, Shumei; Nishizaki, Daisuke; Miyashita, Hirotaka; Pabla, Sarabjot; Nesline, Mary K; Ko, Heidi; Conroy, Jeffrey M; Naing, Aung; Kurzrock, Razelle

PD-L2 Landscape and Correlation with Outcome: An Immunomic Analysis

PD-L2表达谱及其与预后的相关性:一项免疫组学分析

Patwari, Anannya; Nishizaki, Daisuke; Jensen, Taylor; DePietro, Paul; Pabla, Sarabjot; Kato, Shumei; Kurzrock, Razelle

Novel clinical trial designs emerging from the molecular reclassification of cancer

癌症分子重新分类催生了新型临床试验设计。

Nikanjam, Mina; Kato, Shumei; Allen, Teresa; Sicklick, Jason K; Kurzrock, Razelle

Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations

细胞周期蛋白依赖性激酶4/6抑制剂作为治疗伴有GNAS突变的腹膜黏液性癌病的新疗法

Weitz, Jonathan; Nishizaki, Daisuke; Liau, Joy; Patel, Jay; Ng, Isabella; Sun, Siming; Ramms, Dana; Zou, Jingjing; Wishart, Brian; Rull, Jordan; Baumgartner, Joel; Kelly, Kaitlyn; White, Rebekah; Veerapong, Jula; Hosseini, Mojgan; Patel, Hitendra; Botta, Gregory; Gutkind, J Sylvio; Tiriac, Herve; Kato, Shumei; Lowy, Andrew M